172.52
-1.84%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $4.21bn
- Last close × shares
- Volume
- 223.4k
- Shares, 20 Nov 2026
- Price to earnings
- 5751.2
About ICU Medical
From its filings with the US Securities and Exchange Commission
ICU Medical is based in San Clemente, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ICUI. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $2.23bn and net income of $732,000. At that date it held total assets of $4.05bn and shareholders' equity of $2.12bn. By business, Infusion Consumables [Member] brought in 49.7% of revenue, followed by Infusion Systems [Member] at 30.7% and Vital Care at 19.6%. By region, UNITED STATES accounted for 60.8%, followed by EMEA [Member] at 18.5% and APAC [Domain] at 10.4%.
ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions offered on behalf of our joint venture; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.
Headquartered in San Clemente, California, ICU was founded in 1984. Our primary customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. Since our inception we have grown organically and through acquisitions.
In February 2017, we acquired Pfizer Inc.’s (“Pfizer”) Hospira Infusion Systems (“HIS”) business. The HIS acquisition complemented our legacy non-dedicated infusion sets and oncology business by expanding our product portfolio to include a complete intravenous infusion therapy product-line from IV solutions to IV pumps to non-dedicated infusion sets.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2025
- Infusion Consumables [Member] $1.11bn · 49.7%
- Infusion Systems [Member] $684.2m · 30.7%
- Vital Care $437.9m · 19.6%
Latest on ICU Medical
Our reporting
Next results
Due on 18 Feb 2027. Analysts expect earnings of 2.15 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is ICU Medical's ticker?
ICU Medical trades as ICUI on its US listing, under ISIN US44930G1076.
What was ICU Medical's last closing price?
172.52 on 20 Nov 2026. The figure is in USD and is never converted.
When does ICU Medical next report results?
Results are expected on 5 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.